Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 13;13:849598. doi: 10.3389/fphar.2022.849598

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zong, Liang, Wang, Li, Wang, Chen, Zhang, Jiao, Li, Wu, Li, Wang, Liu, Liu, Zhao, Huang, Huang, Wang, Qin, Ma, Wang and Shi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Chest computed tomographic (CT) images of a 66-year-old COVID-19 patient before and after QFPDD. Case 6: A 66-year-old male with severe COVID-19. Panel 2-(A): In both lungs, transmissibility was reduced, and ground-glass opacity and mesh shadows were observed mostly under the pleura and with interstitial involvement. Scattered patchy opacities were observed mainly in the lower lobe of both lungs, and scattered small nodules were present in both lungs. Panel 2-(B): After two courses of QFPDD in combination with conventional treatment, the scattered ground-glass, strip-like, and patchy opacities in both lungs were absorbed and reduced compared to that measured at admission. Panel 2-(C): Ground-glass opacity was further reduced in both lungs before discharge.